|
COMMERCE BUSINESS DAILY ISSUE OF SEPTEMBER 5,1997 PSA#1924National Institutes of Health, National Institute of Allergy and
Infectious Diseases, Contract Management Branch, Solar Bldg., Room
3C07, 6003 Executive Blvd. MSC 7610, Bethesda, MD 20892-7610 A -- CANDIDATE HIV RECOMBINANT CORE VACCINE FOR CLINICAL TRIALS DUE
092597 POC Frederick R. Vogel, (301) 402-3684, E-MAIL: fvlv@nih.gov The
Division of AIDS (DAIDS), NIAID, NIH is conducting a market survey to
determine the availability and capability of developers of a candidate
HIV-1 p55 Gag vaccine. This product should be produced as a particle
that does not package or contain a complete HIV-1 genome. This vaccine
is to be used in clinical testing in humans, therefore the supplied
product must be manufactured under cGMP conditions. This product will
be considered for Phase I clinical trials alone and in combination with
other vaccine products and may eventually be considered for
larger-scale clinical trials. To be considered, developers must: (1)
have an existing relationship with (or be) a manufacturer with
experience in producing HIV candidate vaccines meeting FDA standards
for use in human studies involving healthy volunteers; (2) have
experience with recombinant protein HIV vaccines; and (3) be willing to
supply the candidate vaccine for use in nonhuman primate studies and in
clinical trials of the p55 Gag vaccine antigen in combination with
other vaccines. Interested firms must document their past experience
and technical expertise in each of the above areas. Selected
developer(s) will be asked to develop one or more candidate HIV
vaccines for safety and immunogenicity testing, possibly including
vaccines for HIV subtypes other than clade B. This is not a Request for
Proposal (RFP). NO RFP is available and DAIDS is not committed to make
an award pursuant to this announcement. Interested firms should
furnish 5 copies of their capability information addressing the three
(3) areas cited above, no later than 4:30 p.m. local time on September
25, 1997 to Frederick R. Vogel, Vaccine and Prevention Research
Program, DAIDS/NIAID, 6003 Executive Blvd., Rm. 2A28A, Rockville, MD
20852, Tel. (301) 435-3747, Fax. (301) 402-3684, E-mail fv1v@nih.gov.
(0246) Loren Data Corp. http://www.ld.com (SYN# 0015 19970905\A-0015.SOL)
A - Research and Development Index Page
|
|